Targeting c-Myb expression in human disease

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 2, 2003, Pages 235-248

  Ramsay, Robert G ^a   Barton, Anna L ^a   Gonda, Thomas J ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Antisense; Attenuation; c Myb c Myc; Clinical applications; Epithelial cancers; HIV; Oligodeoxynucleotides (ODNs); Phosphorothioate ODN; Therapy; Transcriptional pausing

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; CYCLOOXYGENASE 2; LIPOSOME; MYC PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN C MYB;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ASTHENIA; COLON CANCER; CONTROLLED STUDY; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; GENE EXPRESSION REGULATION; GENE TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPOTENSION; INFLAMMATION; LIVER DYSFUNCTION; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE C MYC; REVIEW; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENES, MYB; HEMATOPOIESIS; HIV INFECTIONS; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-MYB; RNA, MESSENGER; RNA, NEOPLASM; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 0037396879     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.2.235     Document Type: Review

References (92)

1. CLARK RE: Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia (2000) 14:347-355.
2. GONDA TJ, GOUGH NM, DUNN AR, DE BLAQUIERE J: Nucleotide sequence of cDNA clones of the murine myb proto-oncogene. EMBO J. (1985) 4:2003-2008.
3. WESTON KM: The myb genes. Semin. Cancer Biol. (1990) 1:371-382.
4. WESTON K: Myb proteins in life, death and differentiation. Curr. Opin. Genet. Dev. (1998) 8:76-81.
5. NESS SA: Myb binding proteins: regulators and cohorts in transformation. Oncogene (1999) 18:3039-3046.
6. KLEMPNAUER KH, GONDA TJ, BISHOP JM: Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: the architecture of a transduced oncogene. Cell (1982) 31:453-463.
7. WESTIN EH, WONG-STAAL F, GELMANN EP et al.: Expression of cellular homologues of retroviral onc genes in human hematopoietic cells. Proc. Natl. Acad. Sci. USA (1982) 79:2490-2494.
8. DUPREY SP, BOETTIGER D: Developmental regulation of c-myb in normal myeloid progenitor cells. Proc. Natl. Acad. Sci. USA (1985) 82:6937-6941.
9. FU SL, LIPSICK JS: Constitutive expression of full-length c-Myb transforms avian cells characteristic of both the monocytic and granulocytic lineages. Cell Growth Differ. (1997) 8:35-45.
10. GONDA TJ, RAMSAY RG, JOHNSON GR: Murine myeloid cell lines derived by in vitro infection with recombinant c-myb retroviruses express myb from rearranged vector proviruses. EMBO J. (1989) 8:1767-1775.
11. GONDA TJ, BUCKMASTER C, RAMSAY RG: Activation of c-myb by carboxy-terminal truncation: relationship to transformation of murine haemopoietic cells in vitro. EMBO J. (1989) 8:1777-1783.
12. MUCENSKI ML, MCLAIN K, KIER AB et al.: A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell (1991) 65:677-689.
13. SICURELLA C, FREEMAN R, MICALLEF S, MUCENSKI ML, BERTONCELLO I, RAMSAY RG: Defective stem cell factor expression in c-myb null fetal liver stroma. Blood Cells Mol. Dis. (2001) 27:470-478.
14. THOMPSON MA, ROSENTHAL MA, ELLIS SL et al.: c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression. Cancer Res. (1998) 58:5168-5175.
15. ALEXANDER RJ, BUXBAUM JN, RAICHT RF: Oncogene alterations in rat colon tumors induced by N-methyl-N-nitrosourea. Am. J. Med. Sci. (1992) 303:16-24.
16. ROSENTHAL MA, THOMPSON MA, ELLIS S, WHITEHEAD RH, RAMSAY RG: Colonic expression of c-myb is initiated in utero and continues throughout adult life. Cell Growth Differ. (1996) 7:961-967.
17. ZORBAS M, SICURELLA C, BERTONCELLO I et al.: c-Myb is critical for murine colon development. Oncogene (1999) 18:5821-5830.
18. THOMPSON MA, RAMSAY RG: Myb: an old oncoprotein with new roles. Bioessays (1995) 17:341-350.
19. MELANI C, RIVOLTINI L, PARMIANI G, CALABRETTA B, COLOMBO MP: Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res. (1991) 51:2897-2901.
20. RAMSAY RG, THOMPSON MA, HAYMAN JA, REID G, GONDA TJ, WHITEHEAD RH: Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ. (1992) 3:723-730.
21. BIROCCIO A, BENASSI B, D'AGNANO I et al.:c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am. J. Pathol. (2001) 158:1289-1299.
22. SU AI, WELSH JB, SAPINOSO LM et al.: Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. (2001) 61:7388-7393.
23. JOHNSTONE CN, TEBBUTT NC, ABUD HE, et al.: Characterization of mouse A33 antigen, a definitive marker for basolateral surfaces of intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. (2000) 279:G500-G510.
24. GUERIN M, SHENG ZM, ANDRIEU N, RIOU G: Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene (1990) 5:131-135.
25. KAURANIEMI P, HEDENFALK I, PERSSON K et al.: MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res. (2000) 60:5323-5328.
26. ALEXANDER RJ, BUXBAUM JN, RAICHT RF: Enhanced expression of oncogene-encoded mRNA in rat model of colon cancer. Am. J. Med. Sci. (1991) 301:238-245.
27. ALEXANDER RJ, PANJA A, KAPLAN-LISS E, MAYER L, RAICHT RF: Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease. Dig. Dis. Sci. (1996) 41:660-669.
28. ALITALO K, WINQVIST R, LIN CC, DE LA CHAPELLE A, SCHWAB M, BISHOP JM: Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc. Natl. Acad. Sci. USA (1984) 81:4534-4538.
29. BRABENDER J, LORD RV, DANENBERG KD et al.: Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J. Surg. Res. (2001) 99:301-306.
30. BAER MR, AUGUSTINOS P, KINNIBURGH AJ: Defective c-myc and c-myb RNA turnover in acute myeloid leukemia cells. Blood (1992) 79:1319-1326.
31. THOMPSON MA, FLEGG R, WESTIN EH, RAMSAY RG: Microsatellite deletions in the c-myb transcriptional attenuator region associated with over-expression in colon tumour cell lines. Oncogene (1997) 14:1715-1723.
32. MECHTI N, PIECHACZYK M, BLANCHARD JM, JEANTEUR P, LEBLEU B: Sequence requirements for premature transcription arrest within the first intron of the mouse c-fos gene. Mol. Cell. Biol. (1991) 11:2832-2841.
33. KEENE RG, MUELLER A, LANDICK R, LONDON L: Transcriptional pause, arrest and termination sites for RNA polymerase II in mammalian N- and c-myc genes. Nucleic Acids Res. (1999) 27:3173-3182.
34. XU L, MENG Y, WALLEN R, DEPINHO RA: Loss of transcriptional attenuation in N-myc is associated with progression towards a more malignant phenotype. Oncogene (1995) 11:1865-1872.
35. WEAVER GA, TANGEL CT, KRAUSE JA et al.: Biomarkers of human colonic cell growth are influenced differently by a history of colonic neoplasia and the consumption of acarbose. J. Nutr. (2000) 130:2718-2725.
36. COHEN LA, AMIN S, MARKS PA, RIFKIND RA, DESAI D, RICHON VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. (1999) 19:4999-5005.
37. FRAMPTON J, RAMQVIST T, GRAF T: v-Myb of E26 leukemia virus up-regulates bcl-2 and suppresses apoptosis in myeloid cells. Genes Dev. (1996) 10:2720-2731.
38. TAYLOR D, BADIANI P, WESTON K: A dominant interfering Myb mutant causes apoptosis in T cells. Genes Dev. (1996) 10:2732-2744.
39. COGSWELL JP, COGSWELL PC, KUEHL WM et al.: Mechanism of c-myc regulation by c-Myb in different cell lineages. Mol. Cell. Biol. (1993) 13:2858-2869.
40. NAKAGOSHI H, KANEI-ISHII C, SAWAZAKI T, MIZUGUCHI G, ISHII S: Transcriptional activation of the c-myc gene by the c-myb and B-myb gene products. Oncogene (1992) 7:1233-1240.
41. SCHMIDT M, NAZAROV V, STEVENS L, WATSON R, WOLFF L: Regulation of the resident chromosomal copy of the c-myc by c-Myb is involved in myeloid leukemogenesis. Mol. Cell. Biol. (2000) 20:1970-1981.
42. RAMSAY RG, FRIEND A, VIZANTIOS Y et al.: Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. (2000) 60:1805-1809.
43. TANIKAWA J, ICHIKAWA-IWATA E, KANEI-ISHII C, ISHII S: Regulation of c-Myb activity by tumor suppressor p53. Blood Cells Mol. Dis. (2001) 27:479-482.
44. DASGUPTA P, SAIKUMAR P, REDDY CD, REDDY EP: Myb protein binds to human repeat (LTR) sequences and long terminal LTR-mediated transcription. Proc. Natl. Acad. Sci. USA (1990) 87:8090-8094.
45. CHURCHILL MJ, RAMSAY RG, RHODES DI, DEACON NJ: c-Myb influences HIV type 1 gene expression and virus production. AIDS Res. Hum. Retroviruses (2001) 17:1481-1488.
46. PASTORINO F, STUART D, PONZONI M, ALLEN TM: Targeted delivery of antisense oligonucleotides in cancer. J. Control Release (2001) 74:69-75.
47. PRINS J, DE VRIES EG, MULDER NH: The myc family of oncogenes and their presence and importance in small-cell lung carcinoma and other tumour types. Anticancer Res. (1993) 13:1373-1385.
48. GILES RV, SPILLER DG, TIDD DM: Chimeric oligodeoxynucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anticancer Drug Des. (1993) 8:33-51.
49. GEWIRTZ AM, SOKOL DL, RATZCZAK MZ: Nucleic acid therapeutic: state of the art and future prospects. Blood (1998) 92:712-736.
50. STEIN CA: The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest. (2001) 108:641-644.
51. MILLER PS: Oligonucleoside methylphosphonates as antisense reagents. Biotechnology (NY) (1991) 9:358-362.
52. SUMMERTON J: Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta (1999) 1489:141-158.
53. STEIN CA: Anti-sense oligodeoxynucleotides - promises and pitfalls. Leukemia (1992) 6:967-974.
54. STEIN CA, SUBASINGHE C, SHINOZUKA K, COHEN JS: Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. (1988) 16:3209-3221.
55. MATSUKURA M, SHINOZUKA K, ZON G et al.: Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA (1987) 84:7706-7710.
56. GAO WY, STORM C, EGAN W, CHENG YC: Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol. Pharmacol. (1993) 43:45-50.
57. STEIN CA, CHENG YC: Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science (1993) 261:1004-1012.
58. AKHTAR S, BASU S, WICKSTROM E, JULIANO RL: Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res. (1991) 19:5551-5559.
59. BENNETT CF, CHIANG MY, CHAN H, SHOEMAKER JE, MIRABELLI CK: Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. (1992) 41:1023-1033.
60. COLIGE A, SOKOLOV BP, NUGENT P, BASERGA R, PROCKOP DJ: Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. Biochemistry (1993) 32:7-11.
61. KRONENWETT R, STEIDL U, KIRSCH M, SCZAKIEL G, HAAS R: Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset. Blood (1998) 91:852-862.
62. HENRY SP, GICLAS PC, LEEDS J et al.: Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther. (1997) 281:810-816.
63. WEBB A, CUNNINGHAM D, COTTER F et al.: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet (1997) 349:1137-1141.
64. STUART DD, ALLEN TM: A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta (2000) 1463:219-229.
65. XU Y, SZOKA FC Jr: Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry (1996) 35:5616-5623.
66. TONKINSON JL, STEIN CA: Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. (1994) 22:4268-4275.
67. ZELPHATI O, SZOKA FC Jr: Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA (1996) 93:11493-11498.
68. BURGESS TL, FISHER EF, ROSS SL et al.: The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA (1995) 92:4051-4055.
69. SAIJO Y, UCHIYAMA B, ABE T, SATOH K, NUKIWA T: Contiguous four-guanosine sequence in c-myc antisense phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition. Jpn. J. Cancer Res. (1997) 88:26-33.
70. BENIMETSKAYA L, BERTON M, KOLBANOVSKY A, BENIMETSKY S, STEIN CA: Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-κB p65) 'antisense' oligodeoxynucleotide. Nucleic Acids Res. (1997) 25:2648-2656.
71. YAMAMOTO S, YAMAMOTO T, KATAOKA T, KURAMOTO E, YANO O, TOKUNAGA T: Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity. J. Immunol. (1992) 148:4072-4076.
72. KRIEG AM, YI AK, MATSON S et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549.
73. KRIEG AM, MATSON S, FISHER E: Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. (1996) 6:133-139.
74. NEURATH MF, PETTERSSON S, MEYER ZUM BUSCHENFELDE KH, STROBER W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. (1996) 2:998-1004.
75. DEL BUFALO D, CUCCO C, LEONETTI C et al.: Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br. J. Cancer (1996) 74:387-393.
76. FLAHERTY KT, STEVENSON JP, O'DWYER PJ: Antisense therapeutics: lessons from early clinical trials. Curr. Opin. Oncol. (2001) 13:499-505.
77. MONIA BP, JOHNSTON JF, GEIGER T, MULLER M, FABBRO D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. (1996) 2:668-675.
78. OFFENSPERGER WB, OFFENSPERGER S, WALTER E et al.: In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J. (1993) 12:1257-1262.
79. STATHAM S, MORGAN RA: Gene therapy clinical trials for HIV. Curr. Opin. Mol. Ther. (1999) 1:430-436.
80. FIELD AK: Oligonucleotides as inhibitors of human immunodeficiency virus. Curr. Opin. Mol. Ther. (1999) 1:323-331.
81. ROBERTSON DL, ANDERSON JP, BRADAC JA et al.: HIV-1 nomenclature proposal. Science (2000) 288:55-56.
82. BAYEVER E, IVERSEN PL, BISHOP MR et al.: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial. Antisense Res. Dev. (1993) 3:383-390.
83. LUGER SM, O'BRIEN SG, RATAJCZAK J et al.: Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot study. Blood (2002) 99:1150-1158.
84. FUNATO T, SATOU J, KOZAWA K, FUJIMAKI S, MIURA T, KAKU M: Use of c-myb antisense oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin. Oncol. Rep. (2001) 8:807-810.
85. CAMPANERO MR, ARMSTRONG M, FLEMINGTON E: Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol. Cell. Biol. (1999) 19:8442-8450.
86. BENDER TP, THOMPSON CB, KUEHL WM: Differential expression of c-myb mRNA in murine B lymphomas by a block to transcription elongation. Science (1987) 237:1473-1476.
87. WATSON RJ: A transcriptional arrest mechanism involved in controlling constitutive levels of mouse c-myb mRNA. Oncogene (1988) 2:267-272.
88. CHUBB JM, HOGAN ME: Human therapeutics based on triple helix technology. Trends Biotech. (1992) 10:132-136.
89. MERCOLA D, COHEN JS: Antisense approaches to cancer gene therapy. Cancer Gene Ther. (1995) 2:47-59.
90. SUMMERTON J, WELLER D: Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. (1997) 7:187-195.
91. NISHIKURA K: A short primer on RNAi: RNA-directed RNA polymerase acts as a key catalyst. Cell (2001) 107:415-418.
92. STEIN CA, NARAYANAN R. Antisense oligodeoxynucleotides. Curr. Opin. Oncol. (1994) 6:587-594.